Impact of Active Components on Pulmonary Arterial Hypertension: A Multicenter Study

• Active components significantly reduce clinical worsening in pulmonary arterial hypertension (HR 0.65, p=0.004). • Patients with active components had improved survival compared to those without (log-rank p=0.01). • The benefit was more pronounced in idiopathic PAH, indicating a potential targeted approach. • These findings support the incorporation of active components into PAH management strategies.